Conversely, for the group of genderassociated female tumors (subtypesof breast cancer and endometrioid carcinoma of the uterine corpus), activationof both pathways was a positive prognostic biomarker of OS(Fig. 2A).Interestingly, conflicting trends were observed in the prognosticsignificance of ERK1 and ERK2 pathway activation for sarcoma and thyroidcancer. The gene discussed is MAPK1; the disease is sarcoma.